Previous 10 | Next 10 |
Alkermes (NASDAQ:ALKS) has lost ~12.0% in the post-market after announcing that Janssen Pharmaceutical of Johnson & Johnson (NYSE:JNJ) has notified the company regarding termination of licensing agreements for its NanoCrystal technology. The termination that will become eff...
Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica -- Investor Conference Call Scheduled for Today at 5:00 p.m. ET PR Newswire DUBLIN , Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it r...
Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting PR Newswire DUBLIN , Nov. 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin...
Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences -- Clinical Data, Epidemiology and Health Economics and Outcomes Research to be Shared at Psych Congress, ISAD Conference and NEI Congress -- PR Newswire DU...
The following slide deck was published by Alkermes plc in conjunction with their 2021 Q3 earnings call. For further details see: Alkermes plc 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Alkermes plc (NASDAQ: ALKS) Q3 2021 Earnings Call Oct 27, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Alkermes plc (ALKS) Q3 2021 Earnings Call Transcript
Alkermes plc. (ALKS) Q3 2021 Results Earnings Conference Call October 27, 2021, 08:00 AM ET Company Participants Sandra Coombs - Senior Vice-President of Investor Relations and Corporate Affairs Richard Pops - Chairman & CEO Iain Brown - Senior VP & CFO Todd Nichols - SVP & Chief ...
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been legal for quite some time. Ketamine was originally popul...
Alkermes plc Reports Third Quarter 2021 Financial Results -- Third Quarter Revenues of $294.1 Million Reflect 11% Growth Year-Over-Year -- -- Diluted GAAP Loss per Share of $0.18 and Diluted Non-GAAP Earnings per Share of $0.14 -- -- Company Reiterates Financial Expectat...
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer - Study to Evaluate Intravenous Nemvaleukin in Combination With Pembrolizumab Compared to Investigator's Choice Chemotherapy - PR Newswire DUBLIN , ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...